400614-05-3

Basic information

• Product Name: CYCLOPROPYL 2-METHOXYPHENYL KETONE
• Synonyms: CYCLOPROPYL 2-METHOXYPHENYL KETONE;cyclopropyl(2-methoxyphenyl)methanone
• CAS NO: 400614-05-3
• Molecular Formula: C₁₁H₁₂O₂
• Molecular Weight: 176.21
• Mol File: 400614-05-3.mol

Chemical Properties

• Boiling Point: 277.492°C at 760 mmHg
• Flash Point: 121.159°C
• Appearance: /
• Density: 1.142g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.564
• CAS DataBase Reference: CYCLOPROPYL 2-METHOXYPHENYL KETONE(CAS DataBase Reference)
• NIST Chemistry Reference: CYCLOPROPYL 2-METHOXYPHENYL KETONE(400614-05-3)
• EPA Substance Registry System: CYCLOPROPYL 2-METHOXYPHENYL KETONE(400614-05-3)

Safety Data

• Hazardous Substances Data: 400614-05-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
CYCLOPROPYL 2-METHOXYPHENYL KETONE is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with improved efficacy and safety profiles.
Used in Agrochemical Industry:
CYCLOPROPYL 2-METHOXYPHENYL KETONE is used as a building block in the production of agrochemicals, helping to create effective and environmentally friendly solutions for pest control and crop protection.
Used in Fragrance and Flavor Industry:
CYCLOPROPYL 2-METHOXYPHENYL KETONE is used as a component in the creation of fragrances and flavorings, adding unique scents and tastes to a variety of consumer products.
Used in Material Science:
CYCLOPROPYL 2-METHOXYPHENYL KETONE is used in the field of material science for its potential to contribute to the development of innovative materials with enhanced properties.
Used in Organic Synthesis:
CYCLOPROPYL 2-METHOXYPHENYL KETONE is used as an intermediate in organic synthesis, enabling the production of a wide range of organic compounds for various applications.

InChI:InChI=1/C11H12O2/c1-13-10-5-3-2-4-9(10)11(12)8-6-7-8/h2-5,8H,6-7H2,1H3

Upstream product

• 578-57-4 2-bromoanisole 
• 5500-21-0 cyclopropropanecarbonitrile 
• 16750-63-3 2-methoxyphenylmagnesium bromide 
• 13139-86-1 4-methoxyphenyl magnesium bromide 
• 854304-53-3 cyclopropyl-(2-methoxy-phenyl)-ketone-imine 

Downstream Products

• 444149-33-1 cyclopropanecarboxylic acid o-anisidide 
• 1355988-71-4 α-cyclopropyl-2-methoxystyrene 
• 58713-52-3 2'-methoxy-5,6-dihydro-[1,1'-biphenyl]-3(4H)-one 
• 1196851-96-3 5-[(E)-2-cyclopropyl-2-(2'-methoxyphenyl)vinyl]furo-[2,3-d]pyrimidine-2,4-diamine 

Relevant articles and documents

Ni/Ti Dual Catalytic Cross-Coupling of Nitriles and Organobromides to Access Ketones

Herein, we report the development of a dual catalytic approach for the cross-coupling of nitriles with aryl- and aliphatic-bromides. A titanium(III) catalyst is used to activate nitriles enabling their coupling with organobromides through a nickel catalyst. The Ni/Ti system efficiently prepared unsymmetrical ketones with good chemoselectivity and could selectively couple a bromide in the presence of other functionalizable handles.

Mild Ring Contractions of Cyclobutanols to Cyclopropyl Ketones via Hypervalent Iodine Oxidation

An iodine-mediated oxidative ring contraction of cyclobutanols has been developed. The reaction allows the synthesis of a wide range of aryl cyclopropyl ketones under mild and eco-friendly conditions. A variety of functional groups including aromatic or alkyl halides, ethers, esters, ketones, alkenes, and even aldehydes are nicely tolerated in the reaction. This is in contrast with traditional synthetic approaches for which poor functional group tolerance is often a problem. The practicality of the method is also highlighted by the tunability of iodine oxidation system. Specifically, combining the iodine(III) reagent with an appropriate base allows the reaction to accommodate a range of challenging electron-rich arene substrates. The facile scalability of this reaction is also exhibited herein. (Figure presented.).

Calcium receptor antagonist

A compound of the formula [I] wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.